Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03722498 Terminated - Clinical trials for Hepatocellular Carcinoma

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Start date: June 1, 2016
Phase: Phase 2
Study type: Interventional

To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization(TACE)

NCT ID: NCT03318562 Terminated - Clinical trials for Hepatocellular Carcinoma

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Start date: November 17, 2017
Phase: Phase 2
Study type: Interventional

This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.

NCT ID: NCT03035006 Terminated - Clinical trials for HepatoCellular Carcinoma

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Start date: April 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

NCT ID: NCT02967523 Terminated - Clinical trials for Hepatocellular Carcinoma

Surefire Precision Infusion System Registry

Start date: May 2016
Phase:
Study type: Observational [Patient Registry]

This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE). The purpose is to compare tumor and medical response in a real-world setting as well as identify potential areas for future clinical research.

NCT ID: NCT02950025 Terminated - Pancreatic Cancer Clinical Trials

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Start date: January 19, 2017
Phase: Phase 2
Study type: Interventional

In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this technique to online MR-guided stereotactic body radiation therapy (SBRT) without adaptation. Online plan adaptation increases treatment times for patients and comprises an increased burden on technical and clinical staff. Although preliminary trial results are encouraging, it remains unclear if the dosimetric benefits of online-adaptive planning studies will translate to measurable improvements in clinical outcomes that merit its routine use. In our preliminary study, plan adaptation was most often required when tumors were adjacent to the gastrointestinal tract (the esophagus to the sigmoid colon), as those structures were most commonly the dose-limiting structures and were noted to change in location on a day-to-day basis. For these reasons, abdominal disease sites have historically highlighted the limitations of SBRT. Specifically, the investigators will enroll patients with oligometastatic or unresectable primary disease of the non-liver abdomen to a randomized, prospective trial. Patients will be randomized to one of two treatment arms, in which they will receive either online-adaptive, MRI-guided SBRT or non-adaptive MRI-guided SBRT. Both patient groups will undergo MRI simulation and MRI treatment localization with online MR monitoring and/or gating. All patients will be treated in five fractions over one to two weeks. By adhering to strict normal tissue constraints, the investigators expect toxicity to be within the current standard of care for the non-adaptive arm, with reduction in toxicity in the arm of patients who undergo adaptation based on daily anatomic changes.

NCT ID: NCT02828124 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Start date: August 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

NCT ID: NCT02821533 Terminated - Clinical trials for Hepatocellular Carcinoma

Chemoembolization for Hepatocellular Carcinoma

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The aim of the current study is to study the safety and effectiveness of TACE using a high dose of cisplatin for treatment of HCC. It is hypothesized that the formulation is safe and it improves the therapeutic effect of conventional TACE.

NCT ID: NCT02819869 Terminated - Clinical trials for Hepatocellular Carcinoma

The Combination Effect of Statin Plus Metformin on Relapse-free

Start date: August 1, 2016
Phase: Phase 2
Study type: Interventional

The study demonstrated that either statin or metformin served as notable use in reducing the incidence of many cancers.

NCT ID: NCT02748161 Terminated - Clinical trials for Hepatocellular Carcinoma

DEB-TACE for Hepatocellular Carcinoma

QED
Start date: August 2015
Phase: N/A
Study type: Interventional

Patients enrolled in this study have been diagnosed with hepatocellular carcinoma (HCC) and are scheduled to have a procedure called drug-eluting bead trans-arterial chemoembolization (DEB-TACE). During the DEB-TACE procedure, very small beads are mixed in with a chemotherapy drug, doxorubicin, and delivered to the tumor through an arterial catheter. The DEB-TACE procedure allows the treatment to be delivered directly into the liver. It also causes arterial embolization, the process in which a blood vessel is blocked. Treatment of HCC using DEB-TACE may help delay tumor progression and can downstage (decrease the size) the cancer in order to meet the criteria which may allow patients to become candidates for liver transplantation. The purpose of this study is to compare tumor response and medical outcomes for patients who undergo DEB-TACE with standard endhole catheter versus Surefire® Infusion System.

NCT ID: NCT02704130 Terminated - Clinical trials for Hepatocellular Carcinoma

TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma

Start date: March 2016
Phase: N/A
Study type: Interventional

This single-center, prospective randomized controlled trial (RCT) is designed to compare the outcomes and clinicopathologic results of trans arterial embolization (TAE) and microwave ablation (MWA) combination therapy with MWA monotherapy for the treatment of early (stages 0 and A) hepatocellular carcinoma (HCC). The primary aim of this study is to test the following hypothesis: 2-year intrahepatic disease-free survival does not differ between patients receiving the experimental therapy (MWA + TAE) and patients receiving the standard therapy (MWA alone) as treatment for early stage HCC. Secondary aims are: 1) to determine the clinical feasibility of TAE + MWA in HCC patients with a small tumor burden using patient demographics and disease characteristic data and 2) to determine the effect of TAE on radiographic tumor characteristics in this patient cohort.